OTR3 is a clinical-stage regenerative medical device company developing novel matrix therapies to improve the lives of patients suffering from dermatological and neurological diseases with large unmet medical needs. The company currently is engaged in the development of a second generation of products based on the RGTA® technology while expanding the geographical presence of its marketed products :

• Cacipliq 20®
• Dermapliq
• Clerapliq